Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AV 0113

Drug Profile

AV 0113

Alternative Names: AV-0113; Cancer vaccine - Activartis; Cancer vaccine - Trimed; Dendritic cell vaccine - Activartis; Trivax cancer vaccine

Latest Information Update: 12 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trimed Biotech
  • Developer Activartis Biotech
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • No development reported Glioblastoma; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours

Most Recent Events

  • 08 Sep 2021 No development reported - Phase-II for Glioblastoma (Combination therapy, First-line therapy, Adjuvant therapy) in Austria (Intralymphatic)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Prostate-cancer in Austria (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Sarcoma in Austria (Parenteral, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top